BG2109
Phase 3Small molecule
BG2109 is one of 73 small molecule programs targeting Uterine Fibroid. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
72
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
199 competitors in Endometriosis
#DrugCompanyPhaseTrials
1Orilissa
AbbViePhase 3
Lupron
AbbViePhase 3
Revia
TevaPhase 3
Leuprorelin
TakedaPhase 3
Orgovyx
Sumitomo Pharma America, Inc.Phase 3
Lupron
EEastern Cooperative Oncology Group
Phase 3
Trental
VValidus Pharmaceuticals
Phase 3
Firmagon
FerringPhase 3
Estradiol/norethindrone Acetate
AbbViePhase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ovarian Hyperstimulation1 trial
Uterine Fibroid1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BG2109. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details